Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
|Loading, please wait...|
BIIB News Highlights
- BIIB's 30 day story count now stands at 23.
- Over the past 23 days, the trend for BIIB's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DRUG, DNLI and ADD are the most mentioned tickers in articles about BIIB.
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson’s d
10 Dementia Medications that are Approved or in Clinical Trials
In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, […]
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Medicare Plans to Cover Alzheimer’s Drugs
Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer. The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works. Most Alzheimer’s patients in the U.S. are Medicare enrollees.
Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Medicare Will Pay for Biogen’s Alzheimer’s Drug, With a Caveat
The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry.
15 Best Healthcare Stocks To Buy Now
In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.
Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company
Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...